Arlington Trust’s Bicycle Therapeutics BCYC Stock Holding History

Arlington Trust’s Portfolio BCYC Stock Details BCYC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-53	Closed	-$958	–	529
2023 Q4	$958	Buy	+53	New	+$877	﹤0.01%	836

Other funds holding BCYC

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Tybourne Capital Management Hong Kong $30.9M AUM 20.1% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Westfield Capital Management

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

Arlington Trust's BCYC Position: Q1 2024 in Review

Arlington Trust sold out of Bicycle Therapeutics (BCYC) in Q1 2024, closing a stake of 53 shares — an estimated $958 sold.

Arlington Trust first reported a position in BCYC in Q4 2023 and held it in 1 quarter. The position peaked at $958 in Q4 2023. 95 funds tracked by Wall St. Rank hold BCYC as of Q1 2024.

Arlington Trust reported no remaining Bicycle Therapeutics position as of Q1 2024 after selling out during the quarter.
Arlington Trust sold 53 Bicycle Therapeutics shares in Q1 2024, an estimated $958.
Arlington Trust first reported a position in Bicycle Therapeutics in Q4 2023 and held it in 1 quarter.
Arlington Trust's Bicycle Therapeutics position peaked at $958 in Q4 2023.
95 funds tracked by Wall St. Rank held Bicycle Therapeutics as of Q1 2024.

Based on Arlington Trust's 13F filing for Q1 2024, filed 16 Apr 2024.